The computationofresidualvoltageoffers the theoreticalfoundationto the designofautomaticsecondaryreclose, and it is also the analysisbasis for capacitybraking.
The company is already conducting a big U.S. clinical trial that will compare its stent to Boston Scientific's on actual clinical endpoints such as heart attacks and deaths, rather than just whether it causes arteries toreclose.